Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Blood test using infrared spectroscopy can help detect two cancer types

A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

12 Dec 2017

FDA researchers find underrepresentation of adults aged 75 years and older in blood cancer clinical trials

In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the U.S. Food and Drug Administration found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in this age group, according to research being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.

12 Dec 2017

Study: Combination targeted therapy has high response rates in AML patients

Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers at The University of Texas MD Anderson Cancer Center.

11 Dec 2017

Combination of chemotherapy and targeted drug improves response in younger CLL patients

Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.

11 Dec 2017

Mayo Clinic researchers find emojis to be helpful in assessing patients' quality of life

In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality of life.

11 Dec 2017

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients.

11 Dec 2017

New first line combination therapy shows promising results in patients with advanced NSCLC

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

7 Dec 2017

Study paves way for new therapeutic strategies to impede growth of virus-induced cancers

Researchers at the Cancer Science Institute of Singapore at the National University of Singapore have identified a novel molecular pathway by which a tumor suppressor, TIP60, inhibits the growth of cancer cells.

7 Dec 2017

Clinical study uses genetic testing to match AML patients with new therapies

A clinical trial using genetic testing to match acute myeloid leukemia (AML) patients with new therapies is now open at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

6 Dec 2017

TUM scientists discover emergency shut-off switch for T cell Non-Hodgkin's lymphoma

Safety switches that automatically stop the device for example before it overheats are built into many electrical appliances. Cells are also equipped with such "emergency stop" functions. They make sure that a defective cell doesn't become a tumor cell.

6 Dec 2017

Chemotherapy-generated debris from dead and dying cancer cells can stimulate tumor growth

Cancer therapies including radiation and chemotherapy seek to treat the disease by killing tumor cells. Now a team including researchers at Beth Israel Deaconess Medical Center have shown that the dead and dying cancer cells generated by chemotherapy and targeted cancer therapy paradoxically trigger inflammation that promotes aggressive tumor growth.

1 Dec 2017

Scientists identifies new genetic changes that increase risk of developing Hodgkin lymphoma

People who inherit genetic changes which alter the function of their immune system are at increased risk of developing Hodgkin lymphoma, a major new study reports.

1 Dec 2017

New molecule demonstrates ability to block lymphoma growth

The prestigious scientific journal Clinical Cancer Research has published a study conducted by the research group led by Dr. Francesco Bertoni of the Institute of Oncology Research, that have tested a new molecule that demonstrates its ability to inhibit lymphoma growth.

28 Nov 2017

New cancer drug begins clinical trial in human patients with rare brain tumor

A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain.

28 Nov 2017

Researchers question exclusion of people with prior cancer history from clinical trials

A quarter of newly diagnosed cancer patients 65 or older are survivors who had a prior cancer – often preventing them from participating in clinical trials, researchers from UT Southwestern's Simmons Cancer Center have found.

22 Nov 2017

Study: Cancer patients willing to swap drug efficacy for reduced risk of adverse events

When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a study published online in Blood Advances, a Journal of the American Society of Hematology.

22 Nov 2017

UNC Lineberger professor receives The Leukemia & Lymphoma Society grant for immunotherapy research

UNC Lineberger Comprehensive Cancer Center researcher Barbara Savoldo, MD, PhD, was awarded a $600,000, three-year grant from The Leukemia & Lymphoma Society to support research into an immunotherapy treatment being developed with a "safety switch" to safeguard against potential side effects of the treatment.

21 Nov 2017

Scientists develop novel technology that uses CRISPR to map genetic mutations

A team of scientists led by Virginia Commonwealth University physicist Jason Reed, Ph.D., have developed new nanomapping technology that could transform the way disease-causing genetic mutations are diagnosed and discovered.

21 Nov 2017

Study: Alectinib 600 mg more effective than standard therapy in Asian ALK positive NSCLC patients

A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress.

20 Nov 2017

Researchers discover new way to target cancer without destroying healthy T-cells

A unique approach to targeting the abnormal T-cells that cause T-cell lymphomas could offer hope to patients with the aggressive and difficult-to-treat family of cancers, finds a study involving researchers from Cardiff University.

15 Nov 2017

Lymphoma News and Research

Further Reading

Blood test using infrared spectroscopy can help detect two cancer types

FDA researchers find underrepresentation of adults aged 75 years and older in blood cancer clinical trials

Study: Combination targeted therapy has high response rates in AML patients

Combination of chemotherapy and targeted drug improves response in younger CLL patients

Mayo Clinic researchers find emojis to be helpful in assessing patients' quality of life

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

New first line combination therapy shows promising results in patients with advanced NSCLC

Study paves way for new therapeutic strategies to impede growth of virus-induced cancers

Clinical study uses genetic testing to match AML patients with new therapies

TUM scientists discover emergency shut-off switch for T cell Non-Hodgkin's lymphoma

Chemotherapy-generated debris from dead and dying cancer cells can stimulate tumor growth

Scientists identifies new genetic changes that increase risk of developing Hodgkin lymphoma

New molecule demonstrates ability to block lymphoma growth

New cancer drug begins clinical trial in human patients with rare brain tumor

Researchers question exclusion of people with prior cancer history from clinical trials

Study: Cancer patients willing to swap drug efficacy for reduced risk of adverse events

UNC Lineberger professor receives The Leukemia & Lymphoma Society grant for immunotherapy research

Scientists develop novel technology that uses CRISPR to map genetic mutations

Study: Alectinib 600 mg more effective than standard therapy in Asian ALK positive NSCLC patients

Researchers discover new way to target cancer without destroying healthy T-cells

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News